Nemtabrutinib, Bortezomib, and Rituximab for WM

NCT07464210 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: NEBULA

Sponsor

Seoul National University Hospital